This study investigates pancreatic adenocarcinoma. It evaluates whether a combination of treatments can decrease tumor size, prolong life, and ensure safety for patients.
The study focuses on assessing the safety and effectiveness of a CXCR4 antagonist along with immunotherapy and chemotherapy in patients with metastatic pancreatic adenocarcinoma.
- Who can participate: Adults aged 18 and older with confirmed metastatic pancreatic adenocarcinoma may participate. Participants should have an ECOG performance status of 0 or 1 and meet specific health criteria, including adequate hematological and end-organ function.
- Study details: Participants will receive investigational treatments, including a specific inhibitor, immunotherapy, and chemotherapy. Some may receive a placebo, an inactive substance that looks like the investigational medicine but does not contain any medicine.
How understandable was the trial content above?
Hard to understand
Easy to understand